Sanft named Chief Patient Experience Officer at Smilow Cancer Hospital

Tara Sanft, M.D., associate professor of Medicine (Medical Oncology) and Director of the Smilow Cancer Hospital (SCH) Survivorship Clinic, has been appointed the inaugural Chief Patient Experience Officer at Yale Cancer Center (YCC) and SCH at Yale...
10-Jan-2020 3:35 PM EST Add to Favorites

Mougalian appointed Deputy Chief Ambulatory Officer at Smilow Cancer Hospital

Sarah Mougalian, M.D., assistant professor of Medicine (Medical Oncology) has been named the inaugural Deputy Chief Ambulatory Officer at Smilow Cancer Hospital (SCH) at Yale New Haven Hospital.
10-Jan-2020 3:30 PM EST Add to Favorites

Yale Cancer Center launches Center for Community Engagement and Health Equity

Yale Cancer Center (YCC) announces the launch of the Center for Community Engagement and Health Equity (CEHE). Building on YCC’s longstanding commitment to high-quality, expert, and patient-centered cancer care, screening, and prevention across...
26-Dec-2019 11:50 AM EST Add to Favorites

Backed by Yale Cancer Center research, FDA approves new drug for advanced bladder cancer

The U.S. Food & Drug Administration (FDA) granted accelerated approval to the drug enfortumab vedotin (EV) to treat adult patients with advanced urothelial or bladder cancer.
19-Dec-2019 9:45 AM EST Add to Favorites

Yale Cancer Center researchers investigate inducing “synthetic lethality” in two blood and bone cancers

In a clinical trial led by Yale Cancer Center (YCC) and Smilow Cancer Hospital, researchers aim to exploit DNA mutations in the treatment of two blood and bone marrow cancers, a different tacit than the more traditional approach of blunting or...
10-Dec-2019 10:55 AM EST Add to Favorites

Yale Cancer Center study suggests new approaches needed to manage ibrutinib-related toxicities in CLL patients

New findings by Yale Cancer Center (YCC) and Smilow Cancer Hospital researchers show that as the use of the drug ibrutinib climbs in patients with chronic lymphocytic leukemia (CLL), so do the rates of patients who stop taking the drug.
9-Dec-2019 10:50 AM EST Add to Favorites

Yale Cancer Center study highlights challenges for care of AML patients during initial chemotherapy

A new study by Yale Cancer Center (YCC) researchers shows understanding treatment patterns for patients with acute myeloid leukemia (AML) is vital to develop strategies to improve outcomes.
9-Dec-2019 11:20 AM EST Add to Favorites

Yale Cancer Center researchers show promising new treatment for patients with myelodysplastic syndromes

A new study by Yale Cancer Center (YCC) and Smilow Cancer Hospital researchers suggests that the drug venetoclax aids therapy for relapsed/refractory myelodysplastic syndromes, especially when paired with azacytidine.
9-Dec-2019 11:05 AM EST Add to Favorites

see all news